Literature DB >> 10338470

Diversity of antibody-mediated immunity at the mucosal barrier.

J P Bouvet1, V A Fischetti.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10338470      PMCID： PMC96571          DOI： 10.1128/IAI.67.6.2687-2691.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


× No keyword cloud information.
  54 in total

Review 1.  Antigen sampling across epithelial barriers and induction of mucosal immune responses.

Authors:  M R Neutra; E Pringault; J P Kraehenbuhl
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 2.  Involvement of B-1 cells in mucosal immunity and autoimmunity.

Authors:  M Murakami; T Honjo
Journal:  Immunol Today       Date:  1995-11

3.  Mucosal exudation of plasma is a noninjurious intestinal defense mechanism.

Authors:  C G Persson; B Gustafsson; J S Erjefält; F Sundler
Journal:  Allergy       Date:  1993-11       Impact factor: 13.146

4.  Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

Authors:  A Macpherson; U Y Khoo; I Forgacs; J Philpott-Howard; I Bjarnason
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

5.  The joining (J) chain is present in invertebrates that do not express immunoglobulins.

Authors:  T Takahashi; T Iwase; N Takenouchi; M Saito; K Kobayashi; Z Moldoveanu; J Mestecky; I Moro
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 6.  Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence.

Authors:  M Kilian; J Reinholdt; H Lomholt; K Poulsen; E V Frandsen
Journal:  APMIS       Date:  1996-05       Impact factor: 3.205

7.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  The clinical condition of IgA-deficient patients is related to the proportion of IgD- and IgM-producing cells in their nasal mucosa.

Authors:  P Brandtzaeg; G Karlsson; G Hansson; B Petruson; J Björkander; L A Hanson
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

9.  Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A.

Authors:  D Bessen; V A Fischetti
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

Review 10.  Airway permeability.

Authors:  C G Persson; M Andersson; L Greiff; C Svensson; J S Erjefält; F Sundler; P Wollmer; U Alkner; I Erjefält; B Gustafsson
Journal:  Clin Exp Allergy       Date:  1995-09       Impact factor: 5.018
View more
  22 in total

1.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

Review 2.  Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria.

Authors:  Andrew J Macpherson; Markus B Geuking; Kathy D McCoy
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

3.  The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific.

Authors:  Julia Benckert; Nina Schmolka; Cornelia Kreschel; Markus Josef Zoller; Andreas Sturm; Bertram Wiedenmann; Hedda Wardemann
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium.

Authors:  M Ghaem-Maghami; C P Simmons; S Daniell; M Pizza; D Lewis; G Frankel; G Dougan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individual.

Authors:  Ryan G Gaudet; Felix Breden; Frank Plummer; Jody D Berry
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

7.  Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice.

Authors:  J Y Wu; W F Wade; R K Taylor
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

8.  Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.

Authors:  Praveen Mannam; Kevin F Jones; Bruce L Geller
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 9.  Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces.

Authors:  Jiri Mestecky; Michael W Russell
Journal:  Immunol Lett       Date:  2009-04-05       Impact factor: 3.685

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.